PharmaLundensis AB (XSAT:PHAL) Beginning Cash Position: kr1.16 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:PHAL PharmaLundensis AB XSAT:PHAL
25 GF Score
Price kr0.32
! 1 Warning Sign
View Full Analysis

What is PharmaLundensis AB Beginning Cash Position?

PharmaLundensis AB XSAT:PHAL 25 Beginning Cash Position is kr1.16 Mil as of Mar. 2026. GuruFocus rates XSAT:PHAL with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

PharmaLundensis AB's Beginning Cash Position for the quarter that ended in Mar. 2026 was kr1.16 Mil.

PharmaLundensis AB's quarterly Beginning Cash Position increased from Sep. 2025 (kr1.03 Mil) to Dec. 2025 (kr2.62 Mil) but then declined from Dec. 2025 (kr2.62 Mil) to Mar. 2026 (kr1.16 Mil).

PharmaLundensis AB's annual Beginning Cash Position increased from Dec. 2023 (kr0.35 Mil) to Dec. 2024 (kr2.50 Mil) but then declined from Dec. 2024 (kr2.50 Mil) to Dec. 2025 (kr1.27 Mil).

PharmaLundensis AB Beginning Cash Position Related Terms

PharmaLundensis AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for PharmaLundensis AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaLundensis AB Beginning Cash Position Chart

PharmaLundensis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.35 2.50 1.27

PharmaLundensis AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 2.85 1.03 2.62 1.16
XSAT:PHAL
25GF Score
PharmaLundensis AB XSAT:PHAL
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaLundensis AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr1.16 Mil mean?
PharmaLundensis AB (XSAT:PHAL) has a Beginning Cash Position of kr1.16 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaLundensis AB and its competitors.
Is PharmaLundensis AB's Beginning Cash Position too high?
PharmaLundensis AB's current Beginning Cash Position is kr1.16 Mil. Overall, PharmaLundensis AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does PharmaLundensis AB's Beginning Cash Position compare to VRTX and REGN?
PharmaLundensis AB's Beginning Cash Position of kr1.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on PharmaLundensis AB and its competitors. PharmaLundensis AB's current Beginning Cash Position is kr1.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaLundensis AB stock overvalued right now?
PharmaLundensis AB (XSAT:PHAL) has a current Beginning Cash Position of kr1.16 Mil. The current Beginning Cash Position is kr1.16 Mil. PharmaLundensis AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For PharmaLundensis AB (XSAT:PHAL), the current Beginning Cash Position is kr1.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaLundensis AB Business Description

Address PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
25GF Score

Get the complete analysis for XSAT:PHAL

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price